Synthesis and biological properties of selected 2-aryl-4(3H)-quinazolinones

Heterocyclic Communications

Volumn 10, Issue 4-5, 2004, Pages 325-330

  Eung, Seok Lee ^a   Jong, Keun Sem ^a   Young, Hwa Na ^a   Jahng, Yurngdong ^a  

^a Yeungnam University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1H INDOL 2 YL) 4(3H) QUINAZOLINONE; 2 (QUINOL 2 YL) 4(3H) QUINAZOLINONE; ALKALOID DERIVATIVE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; LUOITONIN A; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; QUINAZOLINONE DERIVATIVE; RUTAECARPINE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL;

EID: 4143132481     PISSN: 07930283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. a) Y. Ashima and K. Kashiwaki, J. Pharm. Soc. Jpn. 35, 1293 (1915).
2. b) E. S. Lee, J. G. Park, and Y. Jahng, Tetrahedron Lett. 44, 1883 (2003), and references therein.
3. a) Z.-Z. Ma, Y. Hano, T. Nomura, and Y.-J. Chen, Heterocycles 46, 541 (1997).
4. b) A. Cagir, S. H. Jones, R. Gao, B. M. Eisenhauer, and S. M. Hecht, J. Am. Chem. Soc. 125, 13628 (2003), and references therein.
5. a) L.-M. Yang,, C.-F. Chen, and K.-H Lee, Bioorg. Med. Chem. Lett. 5, 465 (1995).
6. b) Z-Z. Ma, Y. Hano, T. Nomura, and Y.-J. Chen, Heterocycles 55, 1555 (2001).
7. a) T. C. Moon, M. Murakami, I. Kudo, K. H. Son, H. P. Kim, S. S. Kang, and H. W. Chang, Inflamm. Res. 48, 621 (1999).
8. b) P.-G. Xiao, G.-L. Quo, H.-L Wang, L.-S. Lui, Y.-L. Zheng, Z.-J. Jia, and Z.-B. Deng, Chinese J. Pharmacol. Toxicol. 232 (1988).
9. c) Y. Jahng, Unpublished results.
10. a) H. W. Chang, S. I. Kim, H. Jung, and Y. Jahng, Heterocycles 60, 1359 (2003).
11. b) Y. Jahng, Unpublished results
12. R. P. Thummel, F. Lefoulon, and R. Mahadevan, J. Org. Chem. 50, 3824 (1985).
13. R. P. Thummel and Y. Jahng, J. Org. Chem. 52, 71 (1987).
14. Available from CambridgeSoft Corporataion, Cambridge, MA 02140-2317, USA.
15. I. Fujii, Y. Kobayashi, and N. Hirayama, Z. Kristallogr. 215, 762 (2000).
16. C. A. Fetscher and M. T. Bogert, J. Og. Chem. 4, 71 (1939).
17. a) W. L. F. Armarego, Part I Quinazolines in Fused Pyrimidines ed. by D. J. Brown, Interscience Publishers, New York, 1967, and references therein.
18. b) M. Claesen and H. Vanderhaeghe, Bull. Soc. Chim. Belges. 68, 220 (1959).
19. c) S. S. Joshi and I. R. Gambhir, J. Org. Chem. 26, 3714 (1961).
20. D. T. Zentmeyer and E. C. Wagner, J. Org. Chem. 14, 967 (1949).
21. A.-R. Lee, W.-H. Huang, and J. -Y. Cheng, Chin. Pharm. J. 46, 307 (1994).
22. G. Cignarella, D. Barlocco, P. Vianello, S. Villa, G. A. Pinna, P. Fadda, W. Fratta, L. Toma, and S. Gessi, Il Pharmaco 53, 667 (1998). They reported 1H-indole-2-carbonyl chloride as an intermediate without any physical and spectral data.
23. M. R. Boyd, Princ, Pract. Oncol. 3, 1 (1989)
24. M. T. Bogert, R. A. Gortner, and C. G. Amend, J. Am. Chem. Soc. 33, 949 (1911).
25. L. Berezowski and W. Dymek, Acta Poloniae Pharm. 27, 11 (1970).
26. J. W. David, JR. J. Org. Chem 24, 1691 (1959).
27. J. Bergman and N. Eklund, Chemica Scripta 19, 193 (1982).